CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

Back to UCBJY

Brivaracetam

Phase 3
UCB (UCBJY)
00%
What is LOA?

Phase 3

Development Phase

1

Upcoming Catalysts

0

Historical Events

1

Regulatory Approvals

Upcoming Catalysts
What are catalysts?
Q1 '27
UCBJYPhase 3

Brivaracetam Phase 3 Est. Readout

Brivaracetam
Q1 2027~QSTALE
CT.gov
00%
Competitive Landscape

7 competitors in Epilepsy

BHVNOpakalim
HLUYYbexicaserin
BHVNopakalim
JAZZGWP42003-P
Phase 3
JAZZGWP42003-P 20 mg/kg/day Dose
Phase 3
View Full Landscape
Drug Information

Target Indication

Epilepsy

Clinical Trial

NCT01728077

Last updated: 12/23/2025

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Source: FDA Orange Book
Regulatory Approvals
EMA1/13/2016

Briviact (in Italy: Nubriveo)

Briviact is indicated as adjunctive therapy in the treatment of partial-onset seizures with or without secondary generalisation in adult and adolescent patients from 16 years of age with epilepsy.

View on EMA
Drug Science
Mechanism of action & safety profile
Developer

UCBJY

UCB

Healthcare•North America•NASDAQ
Related Pipeline
SPM 927Phase 3

Partial Seizures With or Without Secondary Generalization

CimziaPhase 3

Crohn Disease

EtanerceptPhase 3

Psoriasis

Certolizumab PegolPhase 3

Rheumatoid Arthritis

Antiepileptic drugs with market authorization available per countryPhase 3

Epilepsy

View full pipeline
Get Catalyst Alerts
Receive weekly digests of upcoming catalysts

Weekly digest every Monday. Unsubscribe anytime.